Invitae (NYSE:NVTA) Earns Hold Rating from Analysts at StockNews.com

Investment analysts at StockNews.com assumed coverage on shares of Invitae (NYSE:NVTA) in a research report issued on Tuesday. The brokerage set a “hold” rating on the medical research company’s stock.

Invitae Stock Performance

NVTA stock opened at $0.00 on Tuesday. The stock has a market capitalization of $106,804.00, a P/E ratio of 0.00 and a beta of 1.59. Invitae has a fifty-two week low of $0.02 and a fifty-two week high of $0.02.

Institutional Trading of Invitae

Several hedge funds have recently added to or reduced their stakes in NVTA. Janney Montgomery Scott LLC lifted its stake in shares of Invitae by 404.6% in the 3rd quarter. Janney Montgomery Scott LLC now owns 63,105 shares of the medical research company’s stock worth $38,000 after acquiring an additional 50,600 shares during the period. Financial Gravity Asset Management Inc. boosted its stake in Invitae by 1,799.5% during the 3rd quarter. Financial Gravity Asset Management Inc. now owns 73,929 shares of the medical research company’s stock valued at $45,000 after purchasing an additional 70,037 shares in the last quarter. SG Americas Securities LLC increased its position in shares of Invitae by 90.7% during the 4th quarter. SG Americas Securities LLC now owns 91,937 shares of the medical research company’s stock valued at $58,000 after purchasing an additional 43,717 shares during the period. Pathstone Family Office LLC raised its stake in shares of Invitae by 94.2% in the 3rd quarter. Pathstone Family Office LLC now owns 157,972 shares of the medical research company’s stock worth $96,000 after buying an additional 76,639 shares in the last quarter. Finally, Prosperity Wealth Management Inc. acquired a new stake in shares of Invitae in the fourth quarter valued at $144,000. Institutional investors own 61.28% of the company’s stock.

Invitae Company Profile

Invitae Corporation, a medical genetics company, that provides genetic information to improve healthcare of people in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, precision oncology, women's health, rare diseases, and pharmacogenomics; digital health solutions; and health data services.